Evidence map›Paper›PMID 42438481›Full record

ArticleNanoscale advances2026

Monodisperse PEG engineering for quantifiable surface conjugation on PLGA nanoparticles.

Ezgi Basavci, Alvja Mali, Marjan Kalati, Raphael Marques Marcilli, Mangala Srinivas

Abstract read
In one paragraph

Article in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ezgi BasavciCell Biology and Immunology, Wageningen University and Research (WUR) Wageningen Netherlands mangala.srinivas@wur.nl.
Alvja MaliCell Biology and Immunology, Wageningen University and Research (WUR) Wageningen Netherlands mangala.srinivas@wur.nl.
Marjan KalatiCell Biology and Immunology, Wageningen University and Research (WUR) Wageningen Netherlands mangala.srinivas@wur.nl.
Raphael Marques MarcilliCell Biology and Immunology, Wageningen University and Research (WUR) Wageningen Netherlands mangala.srinivas@wur.nl.
Mangala SrinivasCell Biology and Immunology, Wageningen University and Research (WUR) Wageningen Netherlands mangala.srinivas@wur.nl.ORCID https://orcid.org/0000-0002-3835-1995

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Surface PEGylation is a well-established strategy to enhance the stability, functionality, and bioavailability of nanoparticles (NPs) in biomedical applications. However, the widespread use of polydisperse PEG derivatives limits the ability to precisely quantify surface PEGylation efficiency (mol%) and evaluate its effect on NP properties. In this study, we present a systematic approach to engineer PLGA NPs using structurally defined monodisperse PEG-diamine derivatives of varying chain lengths (PEG6, PEG26, PEG45), synthesized and purified by chromatographic methods and covalently attached

Identifiers

PMID42438481
PMCPMC13356874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.